Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Scalone, Luciana ^a,b   Cesana, Giancarlo ^a   Furneri, Gianluca ^b   Ciampichini, Roberta ^a   Beck Peccoz, Paolo ^c   Chiodini, Virginio ^a   Mangioni, Silvia ^a   Orsi, Emanuela ^d   Fornari, Carla ^a   Mantovani, Lorenzo Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b CHARTA Foundation   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; CARDIOVASCULAR AGENT; DIGESTIVE TRACT AGENT; HEMATOLOGIC AGENT; INSULIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMPLICATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DATA BASE; DEMOGRAPHY; DIABETES MELLITUS; DRUG COST; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; ICD-9; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MIDDLE AGED; MORTALITY; NATIONAL HEALTH SERVICE; OUTPATIENT; OUTPATIENT CARE; POPULATION RESEARCH; PRESCRIPTION; PREVALENCE; PROBABILITY; PUBLIC HEALTH PROBLEM; SEX DIFFERENCE; VERY ELDERLY; ADOLESCENT; CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; ECONOMICS; FACTUAL DATABASE; INFANT; INSURANCE; ITALY; NEWBORN; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; INSURANCE CLAIM REVIEW; ITALY; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84964313188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113745     Document Type: Article

References (24)

1. Van Dieren S, Beulens JW, van der Schouw YT, Grobbee DE, Neal B (2010) The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 17 Suppl 1: S3-8.
2. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
3. Gnavi R, Karaghiosoff L, Costa G, Merletti F, Bruno G (2008) Socio-economic differences in the prevalence of diabetes in Italy: the population-based Turin study. Nutr Metab Cardiovasc Dis 18(10): 678-82.
4. WHO consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. Availabe: http://whqlibdoc.who.int/hq/1999/who-ncd-ncs-99.2.pdf Accessed 201 September 13.
5. ISTAT, The National Institute of Statistics. Annuario statistico italiano 2013. Available: http://www.istat.it/it/files/2013/12/ASI-2013.pdf Accessed 2014 February 17.
6. Astrup A (2001) Healthy lifestyles in Europe: prevention of obesity and type II diabetes by diet and physical activity. Public Health Nutr 4(2B): 499-515.
7. Hu FB (2011) Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care 34(6): 1249-57.
8. Davis WA, Knuiman MW, Hendrie D, Davis TM (2006) The obesity-driven rising costs of type diabetes in Australia: projections from the Fremantle Diabetes Study. Intern Med J 36(3): 155-61.
9. Kanavos P, van den Aardweg S, Schurer W (2012) Diabetes expenditure, burden of disease and management in 5 EU countries. Available: http://www.lse.ac.uk/LSEHealthAndSocialCare/research/LSEHealth/MTRG/LSEDiabetesReport26Jan2012.pdf Accessed 2014 February 10.
10. Osservatorio ARNO Diabete (2011) Il profilo assistenziale della popolazione con diabete. Rapporto ARNO 2011. Volume XVII-Collana "Rapporti ARNO". Available: http://www.siditalia.it/pubblicazioni Accessed 2014 February 10.
11. Marchesini G, Forlani G, Rossi E, Berti A, De Rosa M on behalf of the ARNO Working Group (2011) The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutr Metab Cardiovasc Dis 21: 339-346.
12. Fellegi IP, Sunter A (1969) A theory of record linkage. JASA 64: 1183-210.
13. Demographic Balance and resident population-Intercensal population estimates 2001-2011. ISTAT, The National Institute of Statistics. Available: http://demo.istat.it/index-e.html Accessed 201 March 12.
14. Lombardo F, Alegiani SS, Maggini M, Raschetti R, Avogardo A, et al. (2007) Prevalenza ed incidenza delle complicanze del diabete: studio DAI. Istituto Superiore di Sanità. Rapporti ISTISAN 07/ 25. Available: http://www.iss.it/publ Accessed 2013 October 05.
15. Monesi L, Baviera M, Marzona I, Avanzini F, Monesi G, et al. (2012) Prevalence, incidence and mortality of diagnosed diabetes: evidence from an Italian population-based study. Diabet Med 29(3): 385-92.
16. Jönsson B, CODE-2 Advisory Board (2002) Revealing the cost of Type II diabetes in Europe. Diabetologia 45(7): S5-12.
17. Ayanian JZ (1999) Using administrative data to assess health care outcomes. Eur Heart J 20: 1689-91.
18. Schneeweiss S, Avorn J (2005) A review of uses of healthcare utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58: 323-37.
19. Mantovani LG, Fornari C, Madotto F, Riva MA, Merlino L, et al. (2011) Burden of acute myocardial infarction. Int J Cardiol 150: 111-112.
20. Newgard CD (2006) Validation of probabilistic linkage to match de-identified ambulance records to a state trauma registry. Acad Emerg Med 13: 69-75.
21. Fornari C, Madotto F, Demaria M, Romanelli A, Pepe P, et al. (2008) Record-linkage procedures in epidemiology: an Italian multicentre study. Epidemiol Prev 32: 79-88.
22. Global Burden of Disease Study 2010. GBD Profile: Italy. Available: http://www.healthdata.org/sites/default/files/files/country-profiles/GBD/ihme-gbd-countr-report-italy.pdf Accessed 2014 September 13.
23. Shahian DM, Silverstein T, Lovett AF, Wolf RE, Normand SLT (2007) Comparison of clinical and administrative data sources for hospital coronary artery bypass graft surgery report cards. Circulation 115: 1518-1527.
24. Suissa S, Garbe E (2007) Primer: administrative health databases in observational studies of drug effects-advantages and disadvantages. Nat Clin Pract Rheumatol 3: 725-732.